It is not the same with or without GalChimia
GalChimia is part of the Neogalfarm project. Its objective is to identify new treatments for oncology, using new therapeutic targets as well as combined therapies. The project is born from a collaboration between AMSlab, NANOGAP, Oncostellae and several research groups from the University of Santiago de Compostela (USC), The Health Research Institute of Santiago de Compostela (IDIS) and LEITAT.
This Project is granted by the Innovation Galician Agency (GAIN) through the Conecta Pyme Program, co-financied by European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Emprego e Industria (Xunta de Galicia). The total budget was fixed at 1,076,339.63 euros.
The objective of the project is based on the elaboration of industrial protocols, using microencapsulated active products, for the detoxification of mussels. Together with the companies Pescados Marcelino, PAYPAY, Mariscos Veiro, Depuradora de Molusco La Sirena and the academic centers ANFACO-CECOPESCA and the International Iberian Nanotechnology Laboratories (INL), GalChimia is taking part to the MytiTox Project.
MytiTox has been financed by the Spanish government and the European Union through the program FEDER INNTERCONECTA 2015. The budget was fixed at 1.461.272,00 euros.
GalChimia, Novozyme, Biochemize, Drop-Tech and four Academic groups participate in the research project HotDrops, whose goal is to develop a new ultrahigh-throughput platform to search for new biocatalysts, with which large enzyme-variant libraries that were previously challenging to handle can now be screened. Single bacterial cells or in vitro transcription/translation systems can be compartmentalised into droplets, each expressing a different gene library variant. This project combined three sciences: enzymology, microfluid technology and organic chemistry. The project has been financed by the European Union through the Seventh Framework Programme (FP7). Click here for more info
GalChimia, Oncostellae and AMSLab are participating in the research project Oncogalfarma, whose goal is to develop new complementary therapies for the treatment of oncological diseases. The research is centred in the fields of inhibitors of protein-protein interactions (PPI) and nuclear receptors. The project has been financed by the government of Galicia and co-financed by the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted was €189,943.59. Click here for more information
The project “Light emitting nanomolecules for biomedical diagnostics applications (LENBDA)” is intended to study the industrial use of a biomolecules detection system based on highly specific luminescent nanoemitters. The system offers a complete solution for detecting biomolecules in a specific, interference-free way. To accomplish this goal, a fully functional prototype of the diagnostic kit will be developed to be used in pathology labs , so no additional equipment will be needed. At the final stage, the project will be validated against tumour cell lines available in tissue banks. The project has been financed by the government of Galicia and the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted was €161,622.94.
GalChimia is a member of the consortium Humanfarma, whose goal is to develop new active compounds for drug discovery through translational research directly in patient samples. The project, which has a budget of €4.1 M and has been partially financed by the Ministry of Economy and Competitiveness under the INNPACTO subprogramme, also involves the participation of the University of Santiago de Compostela (USC), the Barcelona Science Park (PCB) and three biotech companies: Oryzon Genomics, Vivia Allosterics and Vivia Biotech, coordinator of the project.
The biotechnology company Alfama, with sites in Lisbon and Boston, is the world leader in CO-releasing molecule (CORMs), compounds with powerful vasodilatation activity. GalChimia has partnered with Alfama to develop CORMs for the Postoperative Ileus (POI), a condition usually found in patients who have undergone surgery; GalChimia’s synthetic expertise complements the Alfama’s deep biological knowledge of CORMs.
These project was developed in close collaboration with Esteve Quimica and it was funded by the national grant, CDTI. The main objective is to evaluate and develop innovative routes of synthesis for generic products or APIs closed to patent expiry. To do so, it is important to identify new routes with a clear competitive advantage in terms of cost or yield, and/or using intermediaries or catalyser cheaper and/or using cleanest and most efficient technologies.